Biotechnology startup Cerevance Inc. could earn more than $1 billion through a collaboration with drugmaker Merck & Co. to research potential treatments for Alzheimer’s disease.
Boston-based Cerevance agreed to use its technology platform to identify new drug targets Merck can use to develop Alzheimer’s medications. Cerevance said it also has agreed to license a new Alzheimer’s drug program it had been studying to Merck.
Under…
This post first appeared on wsj.com
